Evolus, Inc. (EOLS): Product News News

EOLS – Provides regulatory update, receives Complete Response Letter for BLA for DWP-450.

Key Facts Surrounding This News Item

  • EOLS had returned 0.00% year-to-date leading up to today’s news, versus a +2.00% return from the benchmark S&P 500 during the same period.

More Info About Evolus, Inc. (EOLS)

Evolus, Inc. provides medical aesthetic products for physicians and their patients in the United States. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. The company was founded in 2012 and is based in Irvine, California. View our full EOLS ticker page with ratings, news, and more.

EOLS at a Glance

EOLS Current POWR Rating™
Overall POWR Rating™
EOLS Current Price $16.09 0.56%
More EOLS Ratings, Data, and News

EOLS Price Reaction

The day of this event (May. 16, 2018)
EOLS Closing Price$10.70 26.96%
EOLS Volume2,569,900
1,320.05% from avg
Leading up to this event
EOLS 1-mo return56.18%
After this event
EOLS 1-day return13.21%
EOLS 3-day return9.46%
EOLS 5-day return24.33%

EOLS Price Chart

The Top Stocks For 2019

More Evolus, Inc. (EOLS) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All EOLS News
Page generated in 0.7546 seconds.